Form 4: Lexicon Pharmaceuticals Executive Brian T. Crum Reports Stock Transactions
SEC Form 4 Filing
Brian T. Crum, SVP, General Counsel & Secretary of Lexicon Pharmaceuticals, reports the vesting and subsequent sale of restricted stock units to cover tax obligations.
Summary
- On February 28, 2024, Brian T. Crum, SVP, General Counsel & Secretary of Lexicon Pharmaceuticals, executed transactions involving restricted stock units.
- A total of 68,303 restricted stock units vested and were converted into common stock.
- Crum then disposed of 25,604 shares to cover tax withholding obligations at a price of $2.62 per share.
- Following these transactions, Crum directly owns 177,497 shares of Lexicon Pharmaceuticals common stock.
- He also holds 66,913 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing reflecting standard compensation practices. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 02/28/2024 | Date of earliest transaction: vesting of restricted stock units and sale of shares for tax obligations. |
| 02/29/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.